Author

Yogesh Mahadev Pokharkar

Observed names: Pokharkar, Yogesh, Pokharkar, Yogesh Mahadev, Y., Pokharkar, Yogesh Pokharkar

Institution: Singapore Clinical Research Institute

Observed institutions: National University of Singapore, Ng Teng Fong General Hospital, University of Indonesia, National University Hospital, National University Health System, Singapore Clinical Research Institute, De La Salle Medical and Health Sciences Institute, Makerere University, Padjadjaran University

ORCID: 0000-0002-6180-0234

Observed ORCID: 0000-0002-6180-0234

OpenAlex ID: A5041463778

Treatment Strategy for Rifampin-Susceptible Tuberculosis

2023 · Nicholas I. Paton, Christopher Cousins, et al. · New England Journal of Medicine · 161

Real-World Data on the Diagnosis, Treatment, and Management of Hepatocellular Carcinoma in the Asia-Pacific: The INSIGHT Study

2023 · Yu Ki Sim, Ming Chuen Chong, et al. · Liver Cancer · 53

Comparative clinical evaluation of removable partial denture frameworks fabricated traditionally or with selective laser melting: A randomized controlled trial

2022 · Vanessa Ai Ping Chia, Yoong Liang See Toh, et al. · Journal of Prosthetic Dentistry · 26

Association between Baseline NIHSS Limb Motor Score and Functional Recovery after Stroke: Analysis Based on a Multicountry Dataset

2022 · Christopher Li Hsian Chen, Yogesh Pokharkar, et al. · Cerebrovascular Diseases · 12

Ischemic Stroke and Savings in Time to Achieve Functional Recovery: Experience from NeuroAiD

2023 · Narayanaswamy Venketasubramanian, Yogesh Pokharkar, et al. · Journal of Cardiovascular Development and Disease · 8

Spinal cord injury – assessing tolerability and use of combined rehabilitation and NeuroAiD (SATURN) study – primary results of an exploratory study

2022 · Ramesh Kumar, Ohnmar Htwe, et al. · Journal of Spinal Cord Medicine · 8

Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial

2024 · Nicholas I Paton, Meera Gurumurthy, et al. · The Journal of Infectious Diseases · 6

A randomized cross‐over study of cryopreserved platelets in prophylactic transfusions of thrombocytopenic patients

2023 · Ai Leen Ang, Linda Seo Hwee Gan, et al. · Transfusion · 4

Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)

2025 · Jin Seok Kim, Yang Song, et al. · Blood Cancer Journal · 3

Cost-effectiveness of MLC601 in post-stroke functional recovery compared with placebo - the CHIMES & CHIMES-E studies

2024 · Christopher Li Hsian Chen, Jia Hui Chai, et al. · BMC Health Services Research · 2

CN-105 in Participants with Acute Supratentorial Intracerebral Hemorrhage Trial in Singapore (S-CATCH): A Phase 2b, Randomized, Double-blind, Placebo-Controlled Trial

2026 · Tien Meng Cheong, Michael L. James, et al. · Neurocritical Care · 1

A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)

2025 · Chandramouli Nagarajan, Wei-Ying Jen, et al. · Blood Cancer Journal · 1

Randomized Phase 3 Study of Pomalidomide Cyclophosphamide Dexamethasone (PCD) Versus Pomalidomide Dexamethasone (PD) in Relapse or Refractory Myeloma: An Asian Myeloma Network (AMN) Study

2023 · Yang Song, Jin Seok Kim, et al. · Blood · 1

Daratumumab bortezomib and dexamethasone in transplant ineligible newly diagnosed elderly myeloma patients (AMN006)—a trial by Asian Myeloma Network (NCT03695744)

2025 · Melinda S. Y. Tan, Chandramouli Nagarajan, et al. · Leukemia & lymphoma/Leukemia and lymphoma

Supplementary Material for: Association between Baseline NIHSS Limb Motor Score and Functional Recovery after Stroke: Analysis Based on a Multicountry Dataset

2022 · C.L.H., Chen, Y., Pokharkar, et al. · Figshare

Works count: 18

Citation count: 286

H-index: 6

I10-index: 4